PDCD1 and bone sarcoma: However, a previous study (SARC028) investigating the safety and activity of pembrolizumab, an anti-PD-1 antibody, in patients with advanced soft tissue and bone sarcomas revealed that the activity of pembrolizumab in bone sarcomas was limited, which might be due to the highly suppressive immune microenvironment.